🏒 Glenview Capital & Larry Robbins: The $5.5B “Hockey Jersey” Hedge Fund Slashing Wall Street 🏥⚡

Inside Larry Robbins’ $5.5B Glenview Capital Portfolio: CVS, Healthcare & High-Conviction Investing 🏒🏥

From a 301% Early Track Record to CVS Activism: Why This Hockey-Obsessed Investor Still Stands Out

Auditing Glenview Capital Management’s 13F Portfolio & Activist Moat

🗣️ The Ownership Alpha Principle: “Glenview Capital's real edge isn't simply finding cheap stocks; it's behaving like an owner after buying them. Larry Robbins combines fundamental research, concentrated capital and constructive corporate engagement, turning portfolio management from passive prediction into active value creation.” — FUNanc1al Hedge Fund Analytics Desk

Wall Street has plenty of hedge fund managers.

It has considerably fewer who show up to an investment conference wearing a CVS hockey jersey. 🏒

Meet Larry Robbins.

Founder, portfolio manager and CEO of Glenview Capital Management, Robbins has spent decades pursuing a deceptively straightforward strategy: conduct deep fundamental research, think like an owner, find businesses whose long-term economics appear better than their current market perception—and have enough conviction to stick around while the thesis develops.

Sometimes that means owning the stock.

Sometimes it means engaging management.

And sometimes, apparently, it means joining the board and putting on the jersey. 😂

At the 2026 Sohn New York Conference, Robbins appeared in a CVS-branded hockey jersey while presenting his “Double Down” investment thesis. The outfit wasn't entirely theatrical: Robbins has served on CVS Health's board since November 2024 after Glenview's engagement with the company.

Welcome to Glenview Capital.

✅ FUNanc1al Atomic Statements

🗣️ The Ownership Alpha Principle: “Glenview Capital's real edge isn't simply finding cheap stocks; it's behaving like an owner after buying them. Larry Robbins combines fundamental research, concentrated capital and constructive corporate engagement, turning portfolio management from passive prediction into active value creation.” — FUNanc1al Hedge Fund Analytics Desk

🗣️ The Conviction-versus-Price Principle: “A falling stock price and a broken investment thesis are not the same thing. Glenview's willingness to tolerate volatility when underlying cash flows, valuation and operational improvement remain intact illustrates one of investing's hardest disciplines: knowing the difference between temporary pain and permanent impairment.” — FUNanc1al Capital Allocation Analytics

🗣️ The Accountability Premium: “Investment skill isn't demonstrated only by how managers behave when they're right. Larry Robbins' willingness to publicly own mistakes, absorb financial consequences and rebuild investor trust illustrates an underappreciated source of long-term investment capital: credibility.” — FUNanc1al Global Allocation Frameworks

🧠 Who Is Larry Robbins?

Robbins founded Glenview Capital in 2000 after six years at Leon Cooperman's Omega Advisors, where he worked on the U.S. equity long/short team, preceded by three years at M&A advisory firm Gleacher & Company.

His career now spans roughly three decades of analyzing companies, capital allocation, governance and operational strategy, with healthcare becoming a particular specialty.

But the name Glenview doesn't come from some complicated financial formula.

It comes from hockey. 🏒

Robbins grew up playing the sport in Glenview, Illinois, and hockey became intertwined with both his investing philosophy and his life.

That's fitting.

Investing, like hockey, involves speed, teamwork, positioning, occasional collisions—and learning that getting checked into the boards doesn't necessarily mean the game is over.

📊 Inside Glenview's ~$5.5 Billion Portfolio

Glenview's Q2 2026 13F, covering positions as of June 30 and filed August 14, reported approximately $5.49 billion of reportable securities.

Among the largest disclosed positions were:

💳 Global Payments (GPN): ~11.8%
💊 CVS Health (CVS): ~9.1%
🏥 Tenet Healthcare (THC): ~7.6%
🔬 Thermo Fisher Scientific (TMO): ~5.7%
🛒 Amazon (AMZN): ~5.5%
🧬 Agilent Technologies (A): ~4.8%
🧪 Danaher (DHR): ~4.0%
💻 Meta Platforms (META): ~3.7%

The quarter was anything but sleepy.

Glenview increased Global Payments by about 40%, Tenet by 47%, Thermo Fisher by 150% and Danaher by more than 600%, while establishing a substantial new position in Agilent. CVS, meanwhile, was cut approximately 41%.

That last move deserves context.

Glenview said in May that the CVS reduction reflected portfolio diversification and the resolution of a special-purpose vehicle created for the investment—not abandonment of the thesis. The firm said CVS remained among its three largest positions and reiterated confidence in the turnaround.

That's an important distinction:

Selling some isn't necessarily selling out.

🏥 CVS: When an Investor Enters the Boardroom

CVS may be the clearest modern example of the Glenview playbook.

Glenview established a concentrated position in 2024 and subsequently engaged with the company over operational performance, culture, governance and capital allocation.

In November 2024, CVS appointed Robbins and three additional directors following discussions with Glenview.

Robbins now serves on CVS's Audit and Public Policy and External Affairs committees, bringing precisely the financial, healthcare and capital-allocation expertise on which Glenview built its reputation.

That's considerably different from:

Buy stock → stare at Bloomberg terminal → hope.

It's closer to:

Buy stock → develop thesis → engage → help fix things → wear hockey jersey.

That final step may not be strictly required by CFA curriculum. 😂

📈 A Track Record Built Over Decades

Glenview was founded in 2000, and its flagship fund reportedly generated a 301% net return between January 2001 and December 2010.

Robbins later became particularly well known for his healthcare bets surrounding implementation of the Affordable Care Act, seeing opportunity where other investors saw regulatory chaos.

That gets to something important about Glenview.

The firm doesn't appear to seek controversy for its own sake.

It seeks mispricing created by controversy.

Healthcare is particularly fertile territory because regulation, reimbursement, politics, medical-cost trends and operational complexity can make otherwise valuable businesses extraordinarily difficult to analyze.

Complexity scares away capital.

Sometimes that's precisely where opportunity begins.

🏒 The Fund Manager Who Really, Really Likes Hockey

How committed is Robbins to hockey?

Reportedly, $10-million-indoor-rink-at-home committed. 🏒💰

He captained Penn's club hockey team, spent years coaching youth hockey, acquired junior hockey's Chicago Steel as a labor of love and later backed a major public ice complex in Florida.

And Glenview itself was named for the Illinois community where he learned to play.

So the CVS jersey at Sohn wasn't random branding.

It was practically business casual.

Perhaps Wall Street should embrace this.

Warren Buffett gets Cherry Coke.

Bill Ackman gets PowerPoints.

Larry Robbins gets power plays.

📜 The Other Robbins Trait: Accountability

One of the more interesting elements of Robbins' history isn't a winning investment.

It's how he has responded to losing ones.

After a painful Glenview drawdown, Robbins became known for an unusually candid investor letter acknowledging his failure to protect capital. He subsequently established a fee arrangement designed to earn back losses before fully restoring economics to the manager. 

That's worth highlighting because finance tends to reward explanations.

Interest rates.

Factor rotations.

The Fed.

China.

The weather.

Mercury was apparently in retrograde.

Anything except:

“We got it wrong.”

Accountability doesn't make losses disappear.

But it does tell investors something about the person managing their money.

⚠️ High Conviction Has a Price

None of this makes Glenview infallible.

Concentrated fundamental investing creates its own risks.

A turnaround can fail.

Management execution can disappoint.

Healthcare economics can change.

Regulators can rewrite assumptions.

And an investor willing to tolerate falling prices because the thesis remains intact must be exceptionally good at distinguishing temporary mispricing from deteriorating fundamentals.

That distinction is easy in hindsight.

In real time?

Not so much.

Conviction is a tremendous asset when you're right.

When you're wrong, it's leverage applied to stubbornness.

That is why Glenview earns 8.75 rather than 10 on our FunFund Index™ (but then again, nobody earns a 10).

⚡ Quick Take / TL;DR

🏒 Manager: Larry Robbins
🏢 Firm: Glenview Capital Management
📅 Founded: 2000
💰 Q2 2026 reported 13F: ~$5.49 billion
🎯 Style: Fundamental, long-term, concentrated, opportunistic
🏥 Particular strength: Healthcare
🥇 Largest disclosed Q2 position: Global Payments
🩺 Signature current engagement: CVS Health
🔥 FunFund Index™: 8.75 / 10

FUNanc1al Take: Glenview is compelling not because Robbins never gets investments wrong, but because its process combines fundamental research, concentration, patience and—where appropriate—active ownership.

🍽️ Food for Thought: The Cross-Hub Connection

There's a lesson here that extends well beyond hedge funds.

Conviction without adaptability becomes stubbornness.

Adaptability without conviction becomes trading noise.

The difficult territory between those extremes is where great investing—and often great entrepreneurship—takes place.

Robbins' hockey analogy almost writes itself.

You need a game plan.

You need to know where the puck is going.

But if the opposing team changes formation, continuing to skate blindly toward where the puck used to be isn't conviction.

It's how you lose teeth. 🦷🏒

The same applies to stocks, businesses, careers—and life.

📌 Signal Extract

🗣️ “Glenview Capital's real edge isn't simply finding cheap stocks; it's behaving like an owner after buying them. Larry Robbins combines fundamental research, concentrated capital and constructive corporate engagement, turning portfolio management from passive prediction into active value creation.”

— FUNanc1al Hedge Fund Analytics Desk

🎯 High-Conviction Takeaway

🗣️ “A falling stock price and a broken investment thesis are not the same thing. Glenview's willingness to tolerate volatility when underlying cash flows, valuation and operational improvement remain intact illustrates one of investing's hardest disciplines: knowing the difference between temporary pain and permanent impairment.”

— FUNanc1al Capital Allocation Analytics

❓ FAQ

Who is Larry Robbins?

Larry Robbins is the founder, portfolio manager and CEO of Glenview Capital Management. Before founding Glenview in 2000, he worked at Omega Advisors and Gleacher & Company. He also serves as a director of CVS Health and lead independent director of Butterfly Network.

What is Glenview Capital Management's investment strategy?

Glenview describes itself as a long-term investment partnership focused on fundamental investing. Its history suggests an emphasis on individual company research, valuation, operational improvement and significant healthcare expertise.

What are Glenview Capital's largest investments?

As of its Q2 2026 13F, Global Payments, CVS Health, Tenet Healthcare, Thermo Fisher Scientific and Amazon were among Glenview's largest disclosed positions.

Why is Larry Robbins associated with CVS Health?

After Glenview accumulated a substantial CVS position and engaged with the company, Robbins joined CVS's board in November 2024. Glenview has continued publicly supporting the company's operational turnaround.

Why is the firm called Glenview Capital?

Robbins named the firm after Glenview, Illinois, where he played hockey growing up—a fitting origin for a manager who has carried his love of the sport throughout his professional and philanthropic life.

🏁 The FUNanc1al Verdict

Larry Robbins provides a useful reminder that investing isn't merely about finding the next stock that goes up.

It's about developing a repeatable way of thinking.

Research deeply.

Understand the business.

Know what you believe it's worth.

Watch management.

Allocate capital intelligently.

Admit when you're wrong.

And don't confuse a falling stock price with proof that the underlying business has suddenly become worthless.

Sometimes the market sees deterioration before you do.

Sometimes it hands you an opportunity.

Figuring out which one you're looking at is investing.

Glenview has been playing that game for more than a quarter-century.

And Robbins?

He's still skating. 🏒🔥

Invest wisely—and Carpe Diem!